Back to discover
Disease

Hypertriglyceridemia

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHHypertriglyceridemia
4
Publications
21
Clinical trials
4
Related conditions
1
Related treatments
11
Associated genes
1
Related proteins
2020
Latest publication
Current focus
Therapeutic developmentDiagnosis & biomarkersMetabolic & lifestyle factors
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q4 2026.
  • 2 industry developments reported.
Upcoming Milestones
Clinical Milestones9View all 9
Results expected 5
Recently completed 4
+1 more in the activity timeline below
Industry & Market2View
Activity timeline11

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Clinical trials

13 sponsors · 1 new · 3 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
21
All trials
6
Active
16
Late-stage
6
Completed
Late-stage studies

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

Phase 3 · Recruiting · Arrowhead Pharmaceuticals

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)

Phase 3 · Recruiting · Arrowhead Pharmaceuticals

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypertriglyceridemia

Phase 3 · Recruiting · Beijing Suncadia Pharmaceuticals Co., Ltd

An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)

Phase 3 · Active, not recruiting · Ionis Pharmaceuticals, Inc.

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia

Phase 3 · Active, not recruiting · Arrowhead Pharmaceuticals

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia

Phase 3 · Completed · Arrowhead Pharmaceuticals
Recently completed

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia

Phase 3 · Completed · Arrowhead Pharmaceuticals

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia

Phase 3 · Completed · Arrowhead Pharmaceuticals

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study

Phase 3 · Completed · 89bio, Inc.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia

Phase 3 · Completed · Ionis Pharmaceuticals, Inc.

Phase III, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Cipros 10 Association on Dyslipidemia Treatment

Phase 3 · Completed · EMS

The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia in Patients With Type 2 Diabetes Mellitus

Phase 4 · Completed · Shanghai Jiao Tong University School of Medicine

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2007–2020
Major themes1
  • Tomography, Spiral Computed1
Leading journals3
  • Circulation2
  • JAMA1
  • The New England journal of medicine1
Leading researchers8
  • Agrawal R1
  • Ballantyne C1
  • Ballantyne CM1
  • Barter PJ1
  • Bash D1
  • Berenson GS1
  • Bittner V1
  • Burns TL1
Affiliations (unnormalised)6
  • Academic Medical Center1
  • Baylor College of Medicine1
  • Center for Cardiovascular Disease Prevention1
  • Cleveland Clinic Coordinating Center for Clinical Research1
  • Friedman School of Nutrition Science and Policy1
  • Imperial College of London1

Associated genes

11 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

APOA50.66APOC30.55CELA2A0.47CREB3L30.47GCKR0.44ZPR10.38DGAT10.29FSD20.27APOA40.18HSD17B110.11LIPF0.07

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Gastric triacylglycerol lipasevia LIPF0.07

Related conditions

4 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Cardiovascular Diseases4Hypercholesterolemia2Hypertension2Obesity2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A condition of elevated levels of TRIGLYCERIDES in the blood.

Identifiers
MeSHHypertriglyceridemia
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.